These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8492074)

  • 1. Norethindrone acetate only partially protects the skeleton of rats treated with the LHRH agonist buserelin from oestrogen-deficiency osteopaenia.
    Goulding A; Gold E
    J Endocrinol; 1993 Apr; 137(1):27-33. PubMed ID: 8492074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen in the rat prevents estrogen-deficiency bone loss elicited with the LHRH agonist buserelin.
    Goulding A; Gold E; Feng W
    Bone Miner; 1992 Aug; 18(2):143-52. PubMed ID: 1525595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new way to induce oestrogen-deficiency osteopaenia in the rat: comparison of the effects of surgical ovariectomy and administration of the LHRH agonist buserelin on bone resorption and composition.
    Goulding A; Gold E
    J Endocrinol; 1989 May; 121(2):293-8. PubMed ID: 2502594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive effects of clomiphene citrate on estrogen-deficiency osteopenia elicited by LHRH agonist administration in the rat.
    Goulding A; Fisher L
    J Bone Miner Res; 1991 Nov; 6(11):1177-81. PubMed ID: 1805541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 17 beta-estradiol protects rats from osteopenia associated with administration of the luteinising hormone releasing hormone (LHRH) agonist, buserelin.
    Goulding A; Fisher L
    Bone Miner; 1991 Apr; 13(1):47-53. PubMed ID: 1905969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buserelin-mediated osteoporosis: effects of restoring estrogen on bone resorption and whole body calcium content in the rat.
    Goulding A; Gold E
    Calcif Tissue Int; 1990 Jan; 46(1):14-9. PubMed ID: 2104770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen and norethisterone: effects on plasma cholesterol and total body calcium content in the estrogen-deficient rat.
    Gold E; Stapley S; Goulding A
    Horm Metab Res; 1994 Feb; 26(2):100-3. PubMed ID: 8200611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flutamide-mediated androgen blockade evokes osteopenia in the female rat.
    Goulding A; Gold E
    J Bone Miner Res; 1993 Jun; 8(6):763-9. PubMed ID: 8328318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogens and progestogens conserve bone in rats deficient in calcitonin and parathyroid hormone.
    Goulding A; Gold E
    Am J Physiol; 1989 Dec; 257(6 Pt 1):E903-8. PubMed ID: 2558576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 17 beta-oestradiol and norethisterone acetate on vertebral bone mass and lipid metabolism in early postmenopausal women.
    Ribot C; Tremollieres F; Pouilles JM
    Maturitas; 1992 Dec; 15(3):217-23. PubMed ID: 1465035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys.
    Suparto IH; Williams JK; Cline JM; Anthony MS; Fox JL
    Am J Obstet Gynecol; 2003 May; 188(5):1132-40. PubMed ID: 12748457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone.
    Portman DJ; Symons JP; Wilborn W; Kempfert NJ
    Am J Obstet Gynecol; 2003 Feb; 188(2):334-42. PubMed ID: 12592236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
    Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
    J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of oestrogens and progesterone on oestrogen receptors in female rat liver.
    Marr W; Elder MG; Lim L
    Biochem J; 1980 Sep; 190(3):563-70. PubMed ID: 7470070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of chronic treatment with oestrogen, an oestrogen antagonist and a potent luteinizing hormone releasing hormone agonist analogue on pituitary responsiveness to luteinizing hormone releasing hormone in the rat.
    Hall JM; Whitehead SA
    J Endocrinol; 1983 Sep; 98(3):313-21. PubMed ID: 6413634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the actions of the antiprogestin mifepristone (RU486), the progestin megestrol acetate, the LHRH analog buserelin, and ovariectomy in treatment of rat mammary tumors.
    Bakker GH; Setyono-Han B; Henkelman MS; de Jong FH; Lamberts SW; van der Schoot P; Klijn JG
    Cancer Treat Rep; 1987 Nov; 71(11):1021-7. PubMed ID: 3119199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
    Lamberts SW; Uitterlinden P; de Jong FH
    Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Progress in the contraceptive use of the LH-RH agonist buserelin: intermittent medication with gestagen-induced withdrawal bleeding].
    Hardt W; Schmidt-Gollwitzer K; Nevinny-Stickel J; Schmidt-Gollwitzer M
    Geburtshilfe Frauenheilkd; 1982 Dec; 42(12):874-7. PubMed ID: 6819180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tocotrienol from Bixa orellana (annatto) on bone histomorphometry in a male osteoporosis model induced by buserelin.
    Mohamad NV; Soelaiman IN; Chin KY
    Biomed Pharmacother; 2018 Jul; 103():453-462. PubMed ID: 29674281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.